One Nucleus adds power and influence as senior AstraZeneca executive, Penny James joins the region’s life science membership organisation’s Board
Cambridge, UK: 28 April 2020: One Nucleus, the Cambridge based not-for-profit membership organisation for the East of England-London life sciences cluster, is delighted to announce the appointment of Penny James as a Non-Executive Director. Penny is Chief Operating Officer, Biopharmaceuticals R&D at AstraZeneca, a role she took up in February 2019.
Cambridge, 27th April 2020: The Babraham Research Campus is delighted to confirm Eisai as the latest high-profile organisation to provide financial and mentoring support for its Accelerate@Babraham initiative. The additional funding will further enhance the ability of the Babraham Research Campus to drive innovation in early science concepts and nurture new life science companies within the Cambridge cluster.
Cambridge, UK: Biocair, a specialist logistics company, has recently managed several urgent large-scale shipments of COVID-19 related protective equipment. The company is also supporting many companies and agencies with the swift transportation of testing kits, diagnostic specimens and medical devices.
Cambridge, UK, 22 April 2020: Horizon Discovery Group plc (LSE: HZD) (“Horizon”, “the Company” or “the Group”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that its cGMP-compliant CHOSOURCE™ platform has played a key role in generating a stable cell line for the development of an immunotherapy for autoimmune diseases.
21 April 2020 | The UK Government has announced a ground-breaking new fund that will provide matched financing to UK start-ups and scale-ups.
Taylor Wessing played a leading role in advising the UK Government on the new fund, delivering an unprecedented funding solution in an expedited timeframe.
Angus Miln, partner and head of Taylor Wessing's Corporate Technology group, worked alongside Adrian Rainey and Adam Thatcher from Goodwin Proctor, and Aaron Archer from Cooley LLP and Ylan Steiner from Orrick, Herrington & Sutcliffe LLP.
Cambridge, UK, and Brisbane, CA, 21 April 2020 Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimer
Stevenage Bioscience Catalyst (SBC), a leading location for development and commercialisation of cutting-edge therapeutics, is pleased to announce that Dr Hugo Villanueva is to join as Innovation and Business Development Director in May 2020.
Hugo joins us from Revenant Bio, a research organisation and consultancy supporting and attracting funding for start-ups, spinouts and growing companies in the life sciences sector and has experience of working with Clustermarket.
AMSBIO offer a trio of sterilization systems suitable for a range of applications from sterilizing small laboratory instruments to sterilizing large research facilities.
London, UK, 20th April 2020 / Sciad Newswire / MicrofluidX announces it has raised £1.4m in seed funding from leading seed investors UK Innovation & Science Seed Fund (UKI2S), Longwall Ventures and Moulton Goodies Limited with angel contributions from 88 Capital and Cambridge Angels. The Company will develop its novel cell bioprocessing technology, utilising microfluidics to tackle the challenges associated with bioprocessing for cell and gene therapy.
By George Underwood
April 9, 2020
Face-to-face interactions between pharma and physicians have essentially ceased overnight during the COVID-19 pandemic, but that doesn’t mean HCPs have stopped looking for new medical information.
In fact, they are engaging with digital education platforms more than ever before, suggesting that these channels could fill the gaps now left in pharma’s marketing programmes.